TP53I13

Summary

TP53I13 (tumor protein p53 inducible protein 13, HGNC:25102) is a protein-coding gene on chromosome 17q11.2, encoding Tumor protein p53-inducible protein 13 (Q8NBR0). May act as a tumor suppressor.

Involved in negative regulation of cell cycle; response to UV; and response to xenobiotic stimulus. Located in cytoplasm.

Source: NCBI Gene 90313 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 86 total
• MANE Select transcript: NM_138349

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25102
Approved symbol	TP53I13
Name	tumor protein p53 inducible protein 13
Location	17q11.2
Locus type	gene with protein product
Status	Approved
Aliases	DSCP1
Ensembl gene	ENSG00000167543
Ensembl biotype	protein_coding
Entrez	90313

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 16 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000301057, ENST00000378818, ENST00000577934, ENST00000578073, ENST00000578749, ENST00000579674, ENST00000580132, ENST00000580183, ENST00000581411, ENST00000582829, ENST00000583940, ENST00000584522, ENST00000905153, ENST00000905154, ENST00000905155, ENST00000905156, ENST00000905157, ENST00000923524, ENST00000923525, ENST00000947923, ENST00000947924

RefSeq mRNA: 6 — MANE Select: NM_138349 NM_001346077, NM_001346078, NM_001346079, NM_001346081, NM_001346082, NM_138349

CCDS: CCDS42289

Canonical transcript exons

ENST00000301057 — 7 exons

Exon	Start	End
ENSE00001240720	29572142	29572697
ENSE00001294111	29572812	29573157
ENSE00002715805	29568701	29568830
ENSE00002763445	29569318	29569359
ENSE00002860223	29571857	29572057
ENSE00002876601	29571591	29571719
ENSE00003506956	29569018	29569086

Expression profiles

Bgee: expression breadth ubiquitous, 228 present calls, max score 97.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.0415 / max 193.3241, expressed in 1789 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160105	9.8896	1705
160103	1.2491	643
160099	0.7526	216
160102	0.6194	292
160100	0.5341	307
160101	0.4906	232
160104	0.3620	142
160106	0.1286	45
160098	0.0075	2
160096	0.0043	1

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	97.69	gold quality
adenohypophysis	UBERON:0002196	96.90	gold quality
mucosa of transverse colon	UBERON:0004991	96.74	gold quality
right lobe of liver	UBERON:0001114	95.99	gold quality
small intestine Peyer’s patch	UBERON:0003454	95.93	gold quality
pituitary gland	UBERON:0000007	95.91	gold quality
nerve	UBERON:0001021	95.67	gold quality
tibial nerve	UBERON:0001323	95.67	gold quality
omental fat pad	UBERON:0010414	95.44	gold quality
peritoneum	UBERON:0002358	95.38	gold quality
spleen	UBERON:0002106	95.18	gold quality
left testis	UBERON:0004533	95.01	gold quality
right testis	UBERON:0004534	94.80	gold quality
adipose tissue of abdominal region	UBERON:0007808	94.76	gold quality
left lobe of thyroid gland	UBERON:0001120	94.53	gold quality
right lobe of thyroid gland	UBERON:0001119	94.51	gold quality
transverse colon	UBERON:0001157	94.33	gold quality
small intestine	UBERON:0002108	94.29	gold quality
body of stomach	UBERON:0001161	94.20	gold quality
endocervix	UBERON:0000458	93.96	gold quality
metanephros cortex	UBERON:0010533	93.84	gold quality
apex of heart	UBERON:0002098	93.82	gold quality
left coronary artery	UBERON:0001626	93.73	gold quality
ascending aorta	UBERON:0001496	93.66	gold quality
descending thoracic aorta	UBERON:0002345	93.65	gold quality
thoracic aorta	UBERON:0001515	93.64	gold quality
sural nerve	UBERON:0015488	93.48	gold quality
right lung	UBERON:0002167	93.33	gold quality
thyroid gland	UBERON:0002046	93.32	gold quality
coronary artery	UBERON:0001621	93.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

5 targeting TP53I13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-6809-5P	99.13	68.45	1223

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tp53i13	ENSDARG00000087793
mus_musculus	Trp53i13	ENSMUSG00000044328
rattus_norvegicus	Tp53i13	ENSRNOG00000022615
drosophila_melanogaster	CG12093	FBGN0035372
caenorhabditis_elegans		WBGENE00012755

Protein

Protein identifiers

Tumor protein p53-inducible protein 13 — Q8NBR0 (reviewed: Q8NBR0)

Alternative names: Damage-stimulated cytoplasmic protein 1

All UniProt accessions (8): Q8NBR0, H0Y3E9, J3KRJ1, J3KSX2, K7EJC6, K7EKX3, K7ELD4, K7ERH9

UniProt curated annotations — full annotation on UniProt →

Function. May act as a tumor suppressor. Inhibits tumor cell growth, when overexpressed.

Subcellular location. Cell membrane. Cytoplasm.

Tissue specificity. Expressed in heart, placenta, skeletal muscle, testis, brain and lung.

Induction. Up-regulated by genotoxic stresses of adriamycin and/or UV irradiation in a p53/TP53-dependent manner.

RefSeq proteins (6): NP_001333006, NP_001333007, NP_001333008, NP_001333010, NP_001333011, NP_612358* (*=MANE)

Domains & families (InterPro)

UniProt features (11 total): compositionally biased region 4, topological domain 2, region of interest 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NBR0-F1	61.95	0.07

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 106 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, chr17q11, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE, MODULE_301, GOBP_RESPONSE_TO_UV, GOBP_RESPONSE_TO_RADIATION, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, MYB_Q3, LEF1_Q6, MODULE_188, GOBP_RESPONSE_TO_LIGHT_STIMULUS, YGCGYRCGC_UNKNOWN, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP

GO Biological Process (3): response to xenobiotic stimulus (GO:0009410), response to UV (GO:0009411), negative regulation of cell cycle (GO:0045786)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
response to chemical	1
response to light stimulus	1
cell cycle	1
negative regulation of cellular process	1
regulation of cell cycle	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1332 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TP53I13	C22orf31	O95567	476
TP53I13	TP53TG5	Q9Y2B4	433
TP53I13	KDM4D	Q6B0I6	416
TP53I13	TP53BP2	Q13625	410
TP53I13	TP53I11	O14683	402
TP53I13	USP15	Q9Y4E8	396
TP53I13	MYF6	P23409	389
TP53I13	SDHAF1	A6NFY7	380
TP53I13	CCDC69	A6NI79	377
TP53I13	CSDE1	O75534	368
TP53I13	TP53RK	Q96S44	355
TP53I13	MRPS22	P82650	348
TP53I13	XTBD1	Q96HQ2	348
TP53I13	SACK1A	Q86UY5	347
TP53I13	RSRC1	Q96IZ7	344

IntAct

11 interactions, top by confidence:

A	B	Type	Score
TP53I13	TRIM7	psi-mi:“MI:0915”(physical association)	0.560
TP53I13	KLHL8	psi-mi:“MI:0915”(physical association)	0.560
PCDHB11	CBX4	psi-mi:“MI:0914”(association)	0.350
CLEC12B	GXYLT2	psi-mi:“MI:0914”(association)	0.350
PCDHB11	SDCBP	psi-mi:“MI:0914”(association)	0.350
TMED7	ATP9A	psi-mi:“MI:0914”(association)	0.350
TP53I13	TRIM7	psi-mi:“MI:0915”(physical association)	0.000
TP53I13	KLHL8	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (8): TP53I13 (Affinity Capture-MS), TP53I13 (Two-hybrid), TP53I13 (Two-hybrid), TP53I13 (Affinity Capture-MS), TP53I13 (Affinity Capture-MS), TP53I13 (Affinity Capture-MS), TP53I13 (Affinity Capture-RNA), TP53I13 (Affinity Capture-RNA)

ESM2 similar proteins: A0A0U1RR11, A0A0U1RRI6, A6NCS6, A6NJG2, B0BN44, D3YXK1, E9PY61, E9Q0B3, F5H4A9, O00220, O00221, P09038, P0DPI3, P22083, P98077, Q08AU9, Q2M2W7, Q2M3V2, Q2TBI2, Q5F267, Q5FW56, Q5IS69, Q5R866, Q5T4W7, Q5TM52, Q5U4P2, Q5VTJ3, Q659K9, Q673H1, Q69ZB3, Q6AYE8, Q6IPT2, Q6PJ61, Q7RTU4, Q7TSX9, Q7YR31, Q80SU3, Q86SH2, Q86Y97, Q8NBR0

Diamond homologs: B0BN44, Q5F267, Q8NBR0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

86 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	74
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

905 predictions. Top by Δscore:

Variant	Effect	Δscore
17:29566082:CCA:C	donor_loss	1.0000
17:29566084:A:AT	donor_loss	1.0000
17:29566085:C:CT	donor_loss	1.0000
17:29569082:CGCAG:C	donor_loss	1.0000
17:29569083:GCAGG:G	donor_loss	1.0000
17:29569084:CAGG:C	donor_loss	1.0000
17:29569087:GTA:G	donor_loss	1.0000
17:29569088:T:G	donor_loss	1.0000
17:29571855:A:AG	acceptor_gain	1.0000
17:29571856:G:GG	acceptor_gain	1.0000
17:29566082:CCACC:C	donor_gain	0.9900
17:29566085:CCTG:C	donor_gain	0.9900
17:29568826:GCGAG:G	donor_gain	0.9900
17:29568829:AGGT:A	donor_loss	0.9900
17:29568830:GGTA:G	donor_loss	0.9900
17:29568831:G:GA	donor_loss	0.9900
17:29569012:CCACA:C	acceptor_loss	0.9900
17:29569013:CACA:C	acceptor_loss	0.9900
17:29569014:ACAGG:A	acceptor_loss	0.9900
17:29569015:CA:C	acceptor_loss	0.9900
17:29569016:A:AG	acceptor_gain	0.9900
17:29569016:A:C	acceptor_loss	0.9900
17:29569017:G:GG	acceptor_gain	0.9900
17:29569311:T:G	acceptor_gain	0.9900
17:29569313:TATA:T	acceptor_loss	0.9900
17:29569316:AGGTG:A	acceptor_loss	0.9900
17:29569317:G:GA	acceptor_loss	0.9900
17:29569355:GGCAG:G	donor_gain	0.9900
17:29569356:GCAGG:G	donor_gain	0.9900
17:29569358:AGGT:A	donor_loss	0.9900

AlphaMissense

2463 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:29572652:A:C	S342R	0.978
17:29572654:C:A	S342R	0.978
17:29572654:C:G	S342R	0.978
17:29572822:G:C	K360N	0.978
17:29572822:G:T	K360N	0.978
17:29572663:G:C	W345C	0.968
17:29572663:G:T	W345C	0.968
17:29572637:T:C	F337L	0.964
17:29572639:C:A	F337L	0.964
17:29572639:C:G	F337L	0.964
17:29572562:T:A	W312R	0.963
17:29572562:T:C	W312R	0.963
17:29572564:G:C	W312C	0.959
17:29572564:G:T	W312C	0.959
17:29572569:C:A	A314D	0.955
17:29572599:T:A	L324H	0.955
17:29572626:T:C	L333P	0.951
17:29572616:T:C	C330R	0.945
17:29572623:G:C	R332P	0.940
17:29572599:T:G	L324R	0.939
17:29572608:C:A	A327D	0.936
17:29572633:A:C	R335S	0.936
17:29572633:A:T	R335S	0.936
17:29572661:T:A	W345R	0.936
17:29572661:T:C	W345R	0.936
17:29572818:T:C	L359P	0.936
17:29572599:T:C	L324P	0.935
17:29571607:T:C	F67S	0.933
17:29572590:T:G	L321R	0.933
17:29572614:T:C	L329P	0.933

dbSNP variants (sampled 300 via entrez): RS1000175695 (17:29576336 T>C), RS1000200591 (17:29569356 G>A), RS1000227959 (17:29576095 G>C,T), RS1000271962 (17:29570791 C>G,T), RS1000322357 (17:29570937 CT>C), RS1000500862 (17:29581774 C>A,T), RS1000551274 (17:29574498 G>A,T), RS1000885200 (17:29565265 AAT>A), RS1001001385 (17:29579659 G>A,C), RS1001106829 (17:29580537 G>A), RS1001218093 (17:29582612 C>T), RS1001456607 (17:29580708 G>A), RS1001595270 (17:29565508 T>C,G), RS1001878022 (17:29569974 G>T), RS1001938803 (17:29564547 C>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010703_115	Brain morphology (MOSTest)	1.000000e-28

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cisplatin	increases expression, affects cotreatment	2
Valproic Acid	increases expression, increases methylation	2
dicrotophos	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
methylparaben	affects cotreatment, increases expression	1
mono-(2-ethylhexyl)phthalate	affects cotreatment, decreases expression	1
monobutyl phthalate	decreases expression, affects cotreatment	1
2-ethyl-5-carboxypentyl phthalate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
mono(2-ethyl-5-oxohexyl)phthalate	affects cotreatment, decreases expression	1
mono-benzyl phthalate	decreases expression, increases expression, affects cotreatment	1
mono(2-ethyl-5-hydroxyhexyl) phthalate	affects expression, affects cotreatment, decreases expression, increases expression	1
ICG 001	increases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
mono-isobutyl phthalate	affects cotreatment, decreases expression, increases expression	1
monoethyl phthalate	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	decreases expression	1
Aspirin	increases expression	1
Benzo(a)pyrene	affects methylation	1
Diuron	decreases expression	1
Doxorubicin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Smoke	decreases expression	1
Urethane	increases expression	1
Cyclosporine	decreases expression	1
Cadmium Chloride	increases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.